A MEK-independent role for CRAF in mitosis and tumor progression. - Wikidata - awgldk - TriplyDB

A MEK-independent role for CRAF in mitosis and tumor progression.

A MEK-independent role for CRAF in mitosis and tumor progression.

http://www.wikidata.org/entity/Q35600821

about

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.ETS-targeted therapy: can it substitute for MEK inhibitors?An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.B-Raf regulation of integrin α4β1-mediated resistance to shear stress through changes in cell spreading and cytoskeletal association in T cells Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.Pulmonary squamous cell carcinoma and sorafenib Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation.Kinase-independent role for CRAF-driving tumour radioresistance via CHK2 Hepatoma cells from mice deficient in glycine N-methyltransferase have increased RAS signaling and activation of liver kinase B1.Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position.Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.Endothelial ERK signaling controls lymphatic fate specification Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling.A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal.A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib Cancer-derived immunoglobulin G promotes tumor cell growth and proliferation through inducing production of reactive oxygen species.Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.MEK and RAF inhibitors for BRAF-mutated cancers.Latest Advances Towards Ras Inhibition: A Medicinal Chemistry Perspective.Non-kinase targets of protein kinase inhibitors.MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions.Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.Aurora kinase A interacts with H-Ras and potentiates Ras-MAPK signaling.Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems.Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit.IGF2BP2 promotes colorectal cancer cell proliferation and survival through interfering with RAF-1 degradation by miR-195.Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer.Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2.

P2860

Q27852017-2D3B3461-E4A6-4248-8018-CC8C3F292F3A Q33638827-5F6AD2AA-9B97-4517-9646-227CEF30232F Q33926952-F54497ED-1822-45E4-998C-B6D20F0641AE Q34044770-4623F7FD-855C-4277-9373-FEF379BA8C34 Q34159739-46BC658E-BB52-4F27-B907-B594D4C6342A Q34374407-283C929A-4FB8-4978-90B2-94C63B4C9214 Q34998300-D41F9D38-0758-4D64-8BF1-EDA90AD5C71F Q35790764-B68730CD-81F1-41AF-9530-245460CDD2E2 Q36027249-1CA90865-6BA7-499A-ADAF-1DBE6D191F71 Q36195037-CB423264-97FF-485A-8AEB-710F843A96EE Q36293407-254685ED-B30F-40ED-A9FC-7612CE8D627A Q36357215-ADFC733E-38BF-4A43-B596-48D1B2B560DC Q36638093-84DB9062-C7FD-4C23-86FA-75D5AF123295 Q36739768-A693541C-7497-4160-A92D-BE9D4DADA4F0 Q37029389-CEED5A88-3952-468E-8F15-3311E2C4D44F Q37222225-03C123C5-81A8-4A6A-BED3-477CE3DEF15A Q37332008-CC230940-01CF-483B-8EA8-2D20947B0DC5 Q37424064-BFB4855F-EA7C-468B-92D7-193379F9B865 Q37660216-237A2EA5-9BE8-48B3-A905-48B528570519 Q38051474-3A571E93-067B-419F-8705-BD37174AA309 Q38956084-7CEAE52D-2FFD-4CB8-86E1-1559D746C219 Q39171961-163277BD-2F13-454F-B7A9-575460B48114 Q39618772-D74DEC05-244A-4950-90D5-4EF77BCED256 Q41694346-2BB57795-C759-4768-8366-BBC76621D376 Q42254367-BED44FCA-FA1D-48E9-B168-2F64AF9A2954 Q47123785-A2C18E64-B0A3-40C1-804E-E674F9170CF7 Q49402953-1DE3B7CE-D0DF-45E2-B67E-00DAA6F41A8E Q50075745-50E7DE73-4E04-4471-91FC-3D5C0085F7D4 Q53202333-EAB47827-5753-42D3-B511-385A3830BCEB Q54115748-89043C64-B23B-4E1F-8C86-24C7DBA6B915 Q54976764-B9369F05-43AD-41B3-9B4D-F8F38EE6F4F2 Q55183005-175965AB-5771-49E4-A7E7-297DCC0F1E92

P2860

A MEK-independent role for CRAF in mitosis and tumor progression.

http://www.wikidata.org/entity/Q35600821

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

A MEK-independent role for CRAF in mitosis and tumor progression.

@ast

A MEK-independent role for CRAF in mitosis and tumor progression.

@en

type

label

A MEK-independent role for CRAF in mitosis and tumor progression.

@ast

A MEK-independent role for CRAF in mitosis and tumor progression.

@en

prefLabel

A MEK-independent role for CRAF in mitosis and tumor progression.

@ast

A MEK-independent role for CRAF in mitosis and tumor progression.

@en

P1433

Q35600821-43655492-D3E8-4EBC-8FB6-B8FD72BC9027

P1476

Q35600821-F2E15B83-A089-4B18-BD4F-61884DDB98FA

P2093

Q35600821-426ACC39-238B-4ADF-9ED0-01A21832933D

Q35600821-60DFE58D-EBB4-4F7D-A6BF-8C36E5B2AF00

Q35600821-8CA32F00-F6C0-4971-8B0A-7F5D0B2CA055

Q35600821-CC711D69-3DDC-4AE6-B18F-4EE9B8B21668

Q35600821-CC89366E-0CB8-429B-9AAF-53D390FEEF33

Q35600821-ED40CB2E-F668-4FAE-AC85-D40A5C62F201

Q35600821-F0430D45-B0C4-430A-96EC-AF143A22EF14

Q35600821-F06BF3DB-68F5-4AC2-B72B-21551D3990B0

P2860

Q35600821-17B71DCC-AFA1-4071-B08B-957624B3F928

Q35600821-19CCC95E-76D1-4091-9597-EFD957CBB90C

Q35600821-1A2D4DE6-22EE-49C8-BD3E-301AD8AA8A6C

Q35600821-1A4E8DAD-4789-42E9-84DD-BC4154BF33B3

Q35600821-253D8AFA-D7D8-43CA-B02D-39107D4A3613

Q35600821-25AA9588-5C44-42EE-B91A-AD838FF95347

Q35600821-26F025EB-3BB2-4405-A882-09C4C6EB58CD

Q35600821-282D4722-51D6-4561-8D7E-105265BC5CC4

Q35600821-3302D2FF-9203-46EF-8D89-BC4A20EC8F3A

Q35600821-49FA241F-CAFB-4A28-921A-BB500B84BD33

P2888

Q35600821-CC68FCD3-81C8-45DD-B765-DDEF5CF96EA4

P304

Q35600821-5D8E5299-6EF2-4558-BA3F-6D32395325C3

P31

Q35600821-1D1EBD10-F758-4D7D-9A7E-5D0E41312304

P356

Q35600821-83AFD766-612D-4997-91DB-F45BFE2DD41D

P407

Q35600821-205C6316-4442-4BBF-924C-A5CD322C6E0B

P433

Q35600821-793265E8-4894-49B2-AB52-E9FB8D09AE56

P478

Q35600821-E1E9280A-4F2C-426D-9C11-A69470C32921

P50

Q35600821-B3F1FFBC-1165-472D-A40A-26DF4F49FFC1

Q35600821-DCA6E8CA-1230-407F-9E12-55B4E9446658

P577

Q35600821-41E2213B-21FF-4BAF-A759-7380FB7D2113

P5875

Q35600821-1CF959B6-A1EC-4466-ADCD-E1CE8679FB77

P698

Q35600821-B747736B-65A2-45D1-A024-2322FFE3D899

P932

Q35600821-BB84F2F4-9184-42FD-932D-A53CD124958C

P356

P1433

Nature Medicine

P1476

A MEK-independent role for CRAF in mitosis and tumor progression

@en

P2093

Ainhoa Mielgo

http://www.w3.org/2001/XMLSchema#string

Aleksandra Franovic

http://www.w3.org/2001/XMLSchema#string

David A Cheresh

http://www.w3.org/2001/XMLSchema#string

Eric A Murphy

http://www.w3.org/2001/XMLSchema#string

Maria Fernanda Camargo

http://www.w3.org/2001/XMLSchema#string

Miller Huang

http://www.w3.org/2001/XMLSchema#string

Sara M Weis

http://www.w3.org/2001/XMLSchema#string

Sunil J Advani

http://www.w3.org/2001/XMLSchema#string

P2860

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry

P2888

P304

1641-1645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.2464

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Laetitia Seguin

Sudarshan Anand

P577

2011-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51796340

http://www.w3.org/2001/XMLSchema#string

P698

22081024

http://www.w3.org/2001/XMLSchema#string

P932

3233644

http://www.w3.org/2001/XMLSchema#string